CN107106558A - 具有a2a拮抗剂性质的氨基吡嗪化合物 - Google Patents
具有a2a拮抗剂性质的氨基吡嗪化合物 Download PDFInfo
- Publication number
- CN107106558A CN107106558A CN201580073488.3A CN201580073488A CN107106558A CN 107106558 A CN107106558 A CN 107106558A CN 201580073488 A CN201580073488 A CN 201580073488A CN 107106558 A CN107106558 A CN 107106558A
- Authority
- CN
- China
- Prior art keywords
- methyl
- amino
- pyrazine
- carboxamide
- oxazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1c[n](-c2c(C(F)F)nc(C(N)=O)c(N)n2)nc1 Chemical compound *c1c[n](-c2c(C(F)F)nc(C(N)=O)c(N)n2)nc1 0.000 description 7
- HHWFJRSIUKVJHI-UHFFFAOYSA-N C[n]1nc(CN)c(C2CC2)c1 Chemical compound C[n]1nc(CN)c(C2CC2)c1 HHWFJRSIUKVJHI-UHFFFAOYSA-N 0.000 description 2
- SFEJMKIYOJKHGX-UHFFFAOYSA-N CC(C1CNC(c2nc(C(CO)O)c(-[n]3ncc(C)c3)nc2N)=O)C=Cc2c1cccc2 Chemical compound CC(C1CNC(c2nc(C(CO)O)c(-[n]3ncc(C)c3)nc2N)=O)C=Cc2c1cccc2 SFEJMKIYOJKHGX-UHFFFAOYSA-N 0.000 description 1
- QGLXHKKDEZAHQH-UHFFFAOYSA-N CCC1=CC=CC2C=CC=NC12 Chemical compound CCC1=CC=CC2C=CC=NC12 QGLXHKKDEZAHQH-UHFFFAOYSA-N 0.000 description 1
- AFIBJCBUMHDCHE-VBDYBCAWSA-N CCOC(/C(/[C@H]1C(N)=C1)=N/C(/Cl)=C(\N)/[n]1nccc1)=O Chemical compound CCOC(/C(/[C@H]1C(N)=C1)=N/C(/Cl)=C(\N)/[n]1nccc1)=O AFIBJCBUMHDCHE-VBDYBCAWSA-N 0.000 description 1
- RYNDKNPKBMRWFB-BJMVGYQFSA-N CCc1nccnc1/C=N/O Chemical compound CCc1nccnc1/C=N/O RYNDKNPKBMRWFB-BJMVGYQFSA-N 0.000 description 1
- QAYZLHYSDXJKNY-UHFFFAOYSA-N CCc1nccnc1C=O Chemical compound CCc1nccnc1C=O QAYZLHYSDXJKNY-UHFFFAOYSA-N 0.000 description 1
- NVZFEGUIHFHQMX-UHFFFAOYSA-N CCc1nccnc1CN Chemical compound CCc1nccnc1CN NVZFEGUIHFHQMX-UHFFFAOYSA-N 0.000 description 1
- JFGLJTFTVBZOCB-UHFFFAOYSA-N C[n]1nc(CO)c(Br)c1 Chemical compound C[n]1nc(CO)c(Br)c1 JFGLJTFTVBZOCB-UHFFFAOYSA-N 0.000 description 1
- WLOMFEQRILGMNQ-UHFFFAOYSA-N C[n]1nc(CO)c(C2CC2)c1 Chemical compound C[n]1nc(CO)c(C2CC2)c1 WLOMFEQRILGMNQ-UHFFFAOYSA-N 0.000 description 1
- FDQPHPKMUPYWNL-UHFFFAOYSA-N Cc1c[n](-c2c(C=C)nc(C(NCc3c4ncccc4ccc3)=O)c(N)n2)nc1 Chemical compound Cc1c[n](-c2c(C=C)nc(C(NCc3c4ncccc4ccc3)=O)c(N)n2)nc1 FDQPHPKMUPYWNL-UHFFFAOYSA-N 0.000 description 1
- MEWHKAYEHUKUGF-UHFFFAOYSA-N Nc1nc(-[n]2nccc2)c(C#N)nc1C(O)=O Chemical compound Nc1nc(-[n]2nccc2)c(C#N)nc1C(O)=O MEWHKAYEHUKUGF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081262P | 2014-11-18 | 2014-11-18 | |
| US62/081,262 | 2014-11-18 | ||
| PCT/US2015/060509 WO2016081290A1 (en) | 2014-11-18 | 2015-11-13 | Aminopyrazine compounds with a2a antagonist properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107106558A true CN107106558A (zh) | 2017-08-29 |
Family
ID=56014406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580073488.3A Pending CN107106558A (zh) | 2014-11-18 | 2015-11-13 | 具有a2a拮抗剂性质的氨基吡嗪化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10472347B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3220910B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6779204B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170083136A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107106558A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015350315B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017010261A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2967944C (cg-RX-API-DMAC7.html) |
| MX (1) | MX381180B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2727805C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016081290A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111285798A (zh) * | 2020-04-09 | 2020-06-16 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺盐酸盐的合成方法 |
| CN111423364A (zh) * | 2020-05-19 | 2020-07-17 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺的合成方法 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4302834A3 (en) * | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| EP3594216B1 (en) * | 2017-03-07 | 2022-04-06 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof |
| CN111163780A (zh) | 2017-07-18 | 2020-05-15 | 诺维逊生物股份有限公司 | 作为腺苷拮抗剂的杂环化合物 |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| JP2020532541A (ja) | 2017-08-31 | 2020-11-12 | コーバス・ファーマシューティカルズ・インコーポレイテッド | アデノシンａ２ｂ受容体およびアデノシンａ２ａ受容体を調節するための化合物および方法 |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| US11498923B2 (en) | 2017-12-13 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted imidazo[1,2-c]quinazolines as A2A antagonists |
| JP7361693B2 (ja) | 2017-12-15 | 2023-10-16 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての多環式化合物 |
| WO2020037094A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
| EP3616753A1 (en) * | 2018-08-31 | 2020-03-04 | Corvus Pharmaceuticals, Inc. | Compounds for modulating adenosine a2b receptor and adenosine a2a receptor |
| US12414952B2 (en) | 2018-11-20 | 2025-09-16 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| AU2019383948A1 (en) | 2018-11-20 | 2021-05-20 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| WO2020112700A1 (en) | 2018-11-30 | 2020-06-04 | Merck Sharp & Dohme Corp. | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
| AU2019388872A1 (en) | 2018-11-30 | 2021-05-27 | Merck Sharp & Dohme Llc | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
| MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
| WO2020150676A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| AU2020208644A1 (en) | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| TW202128650A (zh) * | 2019-10-11 | 2021-08-01 | 德商拜耳動物保健有限公司 | 作為殺蟲劑之新穎的雜芳基取代之吡𠯤衍生物 |
| EP3929189A1 (en) * | 2020-06-25 | 2021-12-29 | Bayer Animal Health GmbH | Novel heteroaryl-substituted pyrazine derivatives as pesticides |
| TW202304865A (zh) | 2021-03-23 | 2023-02-01 | 美商百愛及生物醫藥公司 | Nlrp3發炎體之抑制劑 |
| CN119053602A (zh) | 2022-01-28 | 2024-11-29 | 柏奥艾奇实验室公司 | Nlrp3炎性体的n-氧化物抑制剂 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| US12516018B2 (en) * | 2023-03-30 | 2026-01-06 | Brandeis University | Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US12509459B2 (en) | 2024-03-26 | 2025-12-30 | BioAge Labs, Inc. | Inhibitors of NLRP3 inflammasome |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075989A1 (en) * | 2002-12-17 | 2010-03-25 | Astrazeneca Ab | Novel Compounds Having Selective Inhibiting Effect at GSK3 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| WO1995003806A1 (en) | 1993-07-27 | 1995-02-09 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for parkinson's disease |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| DE60110219T2 (de) | 2000-05-26 | 2006-03-09 | Schering Corp. | Adenosin a2a rezeptor antagonisten |
| CA2527033A1 (en) * | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators |
| CA2543644A1 (en) * | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| US20060199828A1 (en) * | 2005-03-04 | 2006-09-07 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| EP2438041A4 (en) * | 2009-06-01 | 2012-11-21 | Merck Sharp & Dohme | PYRAZINE-carboxamide-orexin receptor Antagonist |
-
2015
- 2015-11-13 US US15/525,788 patent/US10472347B2/en active Active
- 2015-11-13 KR KR1020177016281A patent/KR20170083136A/ko not_active Withdrawn
- 2015-11-13 CA CA2967944A patent/CA2967944C/en not_active Expired - Fee Related
- 2015-11-13 MX MX2017006483A patent/MX381180B/es unknown
- 2015-11-13 RU RU2017120853A patent/RU2727805C2/ru active
- 2015-11-13 AU AU2015350315A patent/AU2015350315B2/en not_active Ceased
- 2015-11-13 BR BR112017010261-7A patent/BR112017010261A2/pt not_active IP Right Cessation
- 2015-11-13 EP EP15861650.8A patent/EP3220910B1/en active Active
- 2015-11-13 CN CN201580073488.3A patent/CN107106558A/zh active Pending
- 2015-11-13 WO PCT/US2015/060509 patent/WO2016081290A1/en not_active Ceased
- 2015-11-13 JP JP2017526527A patent/JP6779204B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-19 JP JP2020138418A patent/JP2020193211A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075989A1 (en) * | 2002-12-17 | 2010-03-25 | Astrazeneca Ab | Novel Compounds Having Selective Inhibiting Effect at GSK3 |
Non-Patent Citations (2)
| Title |
|---|
| C BONNEFOUS等: "Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
| 罗焕敏主编: "《神经药理学基础》", 30 June 2011, 暨南大学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111285798A (zh) * | 2020-04-09 | 2020-06-16 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺盐酸盐的合成方法 |
| CN111423364A (zh) * | 2020-05-19 | 2020-07-17 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺的合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015350315A1 (en) | 2017-05-18 |
| BR112017010261A2 (pt) | 2018-02-06 |
| JP2017533946A (ja) | 2017-11-16 |
| EP3220910A1 (en) | 2017-09-27 |
| US10472347B2 (en) | 2019-11-12 |
| CA2967944A1 (en) | 2016-05-26 |
| KR20170083136A (ko) | 2017-07-17 |
| RU2017120853A (ru) | 2018-12-19 |
| WO2016081290A1 (en) | 2016-05-26 |
| JP6779204B2 (ja) | 2020-11-04 |
| CA2967944C (en) | 2020-11-17 |
| EP3220910A4 (en) | 2018-04-25 |
| MX2017006483A (es) | 2017-09-12 |
| MX381180B (es) | 2025-03-12 |
| EP3220910B1 (en) | 2020-01-15 |
| AU2015350315B2 (en) | 2020-06-25 |
| RU2017120853A3 (cg-RX-API-DMAC7.html) | 2019-06-17 |
| RU2727805C2 (ru) | 2020-07-24 |
| US20180327385A1 (en) | 2018-11-15 |
| JP2020193211A (ja) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107106558A (zh) | 具有a2a拮抗剂性质的氨基吡嗪化合物 | |
| TWI795381B (zh) | 作為ｍａｌｔ１抑制劑之吡唑衍生物 | |
| US9896449B2 (en) | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | |
| CN110003200B (zh) | P2x7调节剂 | |
| JP2021042230A (ja) | アザベンズイミダゾール及びａｍａｐ受容体調節因子としてのその使用 | |
| KR20200022027A (ko) | 아데노신 A2A 수용체의 이미다조[1,2,a]피라진 조절물질 | |
| CN102812022A (zh) | 噻唑和噁唑激酶抑制剂 | |
| TW201348226A (zh) | 作為ｐｉｍ抑制劑之醯胺 | |
| HK1210608A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| CN102203093A (zh) | 氨基三唑并吡啶和其作为激酶抑制剂的用途 | |
| CN102548984A (zh) | Pi3激酶和/或mtor的抑制剂 | |
| CN102459249A (zh) | 作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用与制造方法 | |
| US12448368B2 (en) | Indole compounds as androgen receptor modulators | |
| CN111868037B (zh) | 作为crhr2拮抗剂的稠合环状脲衍生物 | |
| TW201506023A (zh) | 新穎吡唑衍生物 | |
| WO2016200717A1 (en) | Aminopyrazine compounds with a2a antagonist properties | |
| CN114630822B (zh) | 联芳基二氢乳清酸脱氢酶抑制剂 | |
| WO2024105363A1 (en) | Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1 | |
| HK40008526B (zh) | P2x7调节剂 | |
| HK40074500B (zh) | 吡嗪化合物和其用途 | |
| HK1222388B (en) | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170829 |
|
| WD01 | Invention patent application deemed withdrawn after publication |